| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:52 UTC |
|---|
| Update Date | 2022-03-07 02:51:58 UTC |
|---|
| HMDB ID | HMDB0015398 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Varenicline |
|---|
| Description | Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. |
|---|
| Structure | [H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21 InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2/t8-,9+ |
|---|
| Synonyms | | Value | Source |
|---|
| 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-H)(3)benzazepine | ChEBI | | Vareniclina | ChEBI | | Vareniclinum | ChEBI | | CP-526,555 | HMDB | | Varenicline tartrate | HMDB | | 6,7,8,9-Tetrahydro-6,10-methano-6H-pyrazino(2,3-H)benzazepine | HMDB | | Tartrate, varenicline | HMDB | | Champix | HMDB | | Chantix | HMDB |
|
|---|
| Chemical Formula | C13H13N3 |
|---|
| Average Molecular Weight | 211.2624 |
|---|
| Monoisotopic Molecular Weight | 211.110947431 |
|---|
| IUPAC Name | (1R,12S)-5,8,14-triazatetracyclo[10.3.1.0²,¹¹.0⁴,⁹]hexadeca-2,4,6,8,10-pentaene |
|---|
| Traditional Name | chantix |
|---|
| CAS Registry Number | 249296-44-4 |
|---|
| SMILES | [H][C@]12C[C@]([H])(CNC1)C1=CC3=NC=CN=C3C=C21 |
|---|
| InChI Identifier | InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2/t8-,9+ |
|---|
| InChI Key | JQSHBVHOMNKWFT-DTORHVGOSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as benzazepines. These are organic compounds containing a benzene ring fused to an azepine ring (unsaturated seven-membered heterocycle with one nitrogen atom replacing a carbon atom). |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Benzazepines |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Benzazepines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Benzazepine
- Diazanaphthalene
- Quinoxaline
- Indane
- Azepine
- Aralkylamine
- Piperidine
- Benzenoid
- Pyrazine
- Heteroaromatic compound
- Secondary aliphatic amine
- Azacycle
- Secondary amine
- Hydrocarbon derivative
- Amine
- Organopnictogen compound
- Organonitrogen compound
- Organic nitrogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.088 g/L | Not Available | | LogP | 0.9 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 151.0 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 1.76 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.0482 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 5.72 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 189.5 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 713.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 235.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 110.0 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 157.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 73.1 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 282.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 251.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 738.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 575.4 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 36.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 854.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 159.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 201.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 595.3 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 418.4 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 183.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Varenicline,1TMS,isomer #1 | C[Si](C)(C)N1C[C@H]2C[C@@H](C1)C1=CC3=NC=CN=C3C=C12 | 2255.8 | Semi standard non polar | 33892256 | | Varenicline,1TMS,isomer #1 | C[Si](C)(C)N1C[C@H]2C[C@@H](C1)C1=CC3=NC=CN=C3C=C12 | 2251.5 | Standard non polar | 33892256 | | Varenicline,1TMS,isomer #1 | C[Si](C)(C)N1C[C@H]2C[C@@H](C1)C1=CC3=NC=CN=C3C=C12 | 2791.8 | Standard polar | 33892256 | | Varenicline,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C[C@H]2C[C@@H](C1)C1=CC3=NC=CN=C3C=C12 | 2497.2 | Semi standard non polar | 33892256 | | Varenicline,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C[C@H]2C[C@@H](C1)C1=CC3=NC=CN=C3C=C12 | 2509.9 | Standard non polar | 33892256 | | Varenicline,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C[C@H]2C[C@@H](C1)C1=CC3=NC=CN=C3C=C12 | 3013.5 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Varenicline GC-MS (Non-derivatized) - 70eV, Positive | splash10-00lr-1910000000-6dbc451aea83e1d014b6 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Varenicline GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Varenicline 10V, Positive-QTOF | splash10-03di-0190000000-4f145434c13b3afcb533 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Varenicline 20V, Positive-QTOF | splash10-03di-0590000000-9e05cfabbf6c1eb096b1 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Varenicline 40V, Positive-QTOF | splash10-0159-3900000000-82a1aaedcfa4ad0c47d4 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Varenicline 10V, Negative-QTOF | splash10-03di-0090000000-213d1987d097fb210ee1 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Varenicline 20V, Negative-QTOF | splash10-03di-0190000000-c719b55058a71a235995 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Varenicline 40V, Negative-QTOF | splash10-01po-3930000000-7accc44141f8030a7a2b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Varenicline 10V, Positive-QTOF | splash10-03di-0090000000-151eb25ddf9df2d6bfbe | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Varenicline 20V, Positive-QTOF | splash10-03di-0090000000-151eb25ddf9df2d6bfbe | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Varenicline 40V, Positive-QTOF | splash10-0lz9-0920000000-ff0909b76eb139f2276a | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Varenicline 10V, Negative-QTOF | splash10-03di-0090000000-4dafdcd63f1115768fe9 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Varenicline 20V, Negative-QTOF | splash10-03di-0090000000-4dafdcd63f1115768fe9 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Varenicline 40V, Negative-QTOF | splash10-0a4i-0190000000-1ec0bedd3eb5b1bc4034 | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT: Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005 May 19;48(10):3474-7. [PubMed:15887955 ]
- Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, Coe JW: Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006 Jan;34(1):121-30. Epub 2005 Oct 12. [PubMed:16221753 ]
- Kuehn BM: FDA speeds smoking cessation drug review. JAMA. 2006 Feb 8;295(6):614. [PubMed:16467225 ]
- Mihalak KB, Carroll FI, Luetje CW: Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006 Sep;70(3):801-5. Epub 2006 Jun 9. [PubMed:16766716 ]
- Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):56-63. [PubMed:16820547 ]
|
|---|